Maxillofacial Prosthesis ImplantationNCT03182361
Implant Survival and Peri-abutment Tissue Reactions of Extra-oral Implants.
A study testing Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants in people with Maxillofacial Prosthesis Implantation and Extra-oral Implants, run by University Hospital, Ghent at 1 site in Belgium.
Trial summary
Patients with craniofacial defects caused by oncologic resection, traumatic events or congenital etiologies suffer from esthetic, functional and psychological problems. Auricular, nasal and orbital defects can be reconstructed with implant retained extra-oral prosthesis. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Maxillofacial Prosthesis Implantation, Extra-oral Implants, Extra-oral Prosthesis
- What is being tested?
- Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteBelgium
- Study dates
- 20 Jun 2017to 17 Oct 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- All patients with auricular, nasal, orbital defects caused by congenital, traumatic, oncologic or infectious etiologies
- Adults (>18yr)
Who cannot join
- Children
- Implant placement for bone anchored hearing aid (BAHA)
- Implant placement for oral rehabilitation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Implant Survival and Peri-abutment Tissue Reactions of Extra-oral Implants: An Interventional Study of 10 Patients
Patients with craniofacial defects caused by oncologic resection, traumatic events or congenital etiologies suffer from esthetic, functional and psychological problems. Auricular, nasal and orbital defects can be reconstructed with implant retained extra-oral prosthesis. The goal of this study is to evaluate implant survival in temporal, maxillary and orbital bone, and peri-implant tissue reactions using a new implant system developed by BioComp Industries.
Read the detailed description
Protocol:
- Planning The ideal size and location of the implants is based on pre-operative CT or CBCT scan followed by analysis using romexis planning software. In normal circumstances, without bone limitations, the number and location of the implants will be planned as mentioned below:
- Left auricular region: 2 implants placed on position 4h and 1h30 in the temporal/mastoid bone. If necessary, 3 implants are placed on positions 1h30, 3h and 4h30. The inter implant distance is 20mm.
- Right auricular region: 2 implants placed on position 8h and 10h30 in the temporal/mastoid bone. If necessary, 3 implants are placed on positions 10h30, 9h and 7h30. The inter implant distance is 20mm.
- Nasal region: 2 implants placed in the lateral parts of the piriform aperture of the maxilla, as far away from the spina nasalis anterior as possible. If necessary a third implant will be placed in the glabella.
- Left orbital region: 2-4 implants are placed in the supra-orbital, lateral and/or infra-orbital rim on positions 1h, 2h, 3h en 5h.
- Right orbital region: 2-4 implants are placed in the supra-orbital, lateral and/or infra-orbital rim on positions 11h, 10h, 9h en 7h. If for some reason there is insufficient bone in the above mentioned areas, the position of the implants will be minimally adjusted in order to secure good osseointegration. Neuronavigation will be used for cases with limited bone volume.
- Flap design During surgery the first step is the creation of a skin flap or resection of a tumor, exposing the area for implantation.
- Implantation The implantation protocol as described by BioComp Industries will be used. Each drilling procedure is executed by 1800-2000rpm with water cooling.
- Defining the implant location with the 2,45mm diameter round bur.
- Preparation of the implant site with the implant drills, length and diameter of the drill is dependent on the length and diameter of the implant. Drilling protocol will always start with the smallest and shortest drill and gradually expanded, corresponding to the size of the implants.
- Placement of the implant without water cooling at 15rpm and maximal torque of 52Ncm. If necessary the implant will be inserted manually. For auricular, orbital and nasal defects with sufficient bone volume (>=3mm) and good bone quality, a percutaneous healing abutment with torque 20-25 ncm will be placed immediately after insertion of the implant (=one-stage protocol). Soft tissues in an area of 15-20mm surrounding the implant will be reduced to 1mm thickness. In all other circumstances, the implant will be protected by means of a cover screw and reburied under the skin for a 3 month osseointegration period (=two-stage protocol). After 3 months the implants are exposed, percutaneous healing abutments placed and the surrounding soft tissues reduced to 1mm thickness. In the case of large resections where no viable skin is left, a split thickness skin graft from the upper thigh will be used. Finally, a healing cap surrounding the healing abutments is placed to ensure strong bone-skin contact around the implant. This healing cap will be fixated by a fixation screw, torqued at 15 Ncm.
- Clinical measurements: The stability of the implants will be measured at the time of abutment placement, 1 or 2 weeks, 1 month, 3 months, 6 months and yearly until the end of the study by resonance frequency analysis (RFA), using the Osstell idx system. At the same time periods the peri-abutment tissue will be evaluated according to the Holgers criteria. Once all implants have reached a stability measurement of 50 ISQ, the patient will be sent to the anaplastologist for prosthesis treatment. In case one or more of the implants fail during the study period, the implant will be removed and replaced by a new implant. The protocol will restart for the newly placed implant.
- Radiological measurements:
The bone level around the implants will be measured at 1 or 2 weeks after implant placement and 1 year after implant placement. Radiological imaging will be performed using a cone beam computed tomography device (planmeca promax 3d max) or CT scan, dependent on primary imaging in order to allow comparison between both images.
- Conditions
- Maxillofacial Prosthesis Implantation, Extra-oral Implants, Extra-oral Prosthesis, Prostheses and Implants
- Being tested
- Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants
- Keywords
- Auricular, nasal, orbital, extraoral prostheses, extraoral implants, peri-implant reactions, Holgers
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implantsDevice
Also called EO-1110-34VD04, EO-1110-40VD03, EO-1110-40VD04
Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
| Study group | Role | What they receive |
|---|---|---|
| Study group | Experimental | Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants Receives: Device: Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants |
What is being measured
The primary outcome is the main question the study is designed to answer.
Implant survival
Implant stability measurement with Osstell IDX system
Measured: 1 year
Peri-implant tissue reaction
Measurement of peri-implant pockets and soft tissue according to Holgers criteria
Measured: 1 year
Secondary outcomes (1)
Bone level
Bone level measurement using CBCT or CT scan
Measured: 1-2 weeks post-operative, 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2017
- Study start20 Jun 2017
- Primary completion17 Oct 2019
- Study completion17 Oct 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Maxillofacial Prosthesis ImplantationStudies of the same condition, open and under way.
- More trials run by University Hospital, GhentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Ghent
- Sponsor type
- University, hospital or other
- Collaborators
- BioComp Industries bv
- Responsible party
- Sponsor
- Investigators
- Hubert Vermeersch, MD, PhD, Principal investigator, Em. Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03182361
- Sponsor's protocol ID
- 2017/0282
- Other IDs
- B670201731744
- Status last verified
- Dec 2022
- First submitted
- 2 May 2017
- Last updated
- 23 Dec 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implant Survival and Peri-abutment Tissue Reactions of Extra-oral Implants: An Interventional Study of 10 Patients
- ClinicalTrials.gov ID
- NCT03182361
- Acronym / sponsor ID
- 2017/0282
- Conditions
- Maxillofacial Prosthesis Implantation, Extra-oral Implants, Extra-oral Prosthesis, Prostheses and Implants
- Keywords
- Auricular, nasal, orbital, extraoral prostheses, extraoral implants, peri-implant reactions, Holgers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University Hospital, GhentUniversity, hospital or other
- Collaborators
- BioComp Industries bv
- Study start
- 20 Jun 2017 (actual)
- Primary completion
- 17 Oct 2019 (actual)
- Study completion
- 17 Oct 2019 (actual)
- First posted
- 9 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with craniofacial defects caused by oncologic resection, traumatic events or congenital etiologies suffer from esthetic, functional and psychological problems. Auricular, nasal and orbital defects can be reconstructed with implant retained extra-oral prosthesis. The goal of this study is to evaluate implant survival in temporal, maxillary and orbital bone, and peri-implant tissue reactions using a new implant system developed by BioComp Industries.
Detailed description
Protocol:
- Planning The ideal size and location of the implants is based on pre-operative CT or CBCT scan followed by analysis using romexis planning software. In normal circumstances, without bone limitations, the number and location of the implants will be planned as mentioned below:
- Left auricular region: 2 implants placed on position 4h and 1h30 in the temporal/mastoid bone. If necessary, 3 implants are placed on positions 1h30, 3h and 4h30. The inter implant distance is 20mm.
- Right auricular region: 2 implants placed on position 8h and 10h30 in the temporal/mastoid bone. If necessary, 3 implants are placed on positions 10h30, 9h and 7h30. The inter implant distance is 20mm.
- Nasal region: 2 implants placed in the lateral parts of the piriform aperture of the maxilla, as far away from the spina nasalis anterior as possible. If necessary a third implant will be placed in the glabella.
- Left orbital region: 2-4 implants are placed in the supra-orbital, lateral and/or infra-orbital rim on positions 1h, 2h, 3h en 5h.
- Right orbital region: 2-4 implants are placed in the supra-orbital, lateral and/or infra-orbital rim on positions 11h, 10h, 9h en 7h. If for some reason there is insufficient bone in the above mentioned areas, the position of the implants will be minimally adjusted in order to secure good osseointegration. Neuronavigation will be used for cases with limited bone volume.
- Flap design During surgery the first step is the creation of a skin flap or resection of a tumor, exposing the area for implantation.
- Implantation The implantation protocol as described by BioComp Industries will be used. Each drilling procedure is executed by 1800-2000rpm with water cooling.
- Defining the implant location with the 2,45mm diameter round bur.
- Preparation of the implant site with the implant drills, length and diameter of the drill is dependent on the length and diameter of the implant. Drilling protocol will always start with the smallest and shortest drill and gradually expanded, corresponding to the size of the implants.
- Placement of the implant without water cooling at 15rpm and maximal torque of 52Ncm. If necessary the implant will be inserted manually. For auricular, orbital and nasal defects with sufficient bone volume (>=3mm) and good bone quality, a percutaneous healing abutment with torque 20-25 ncm will be placed immediately after insertion of the implant (=one-stage protocol). Soft tissues in an area of 15-20mm surrounding the implant will be reduced to 1mm thickness. In all other circumstances, the implant will be protected by means of a cover screw and reburied under the skin for a 3 month osseointegration period (=two-stage protocol). After 3 months the implants are exposed, percutaneous healing abutments placed and the surrounding soft tissues reduced to 1mm thickness. In the case of large resections where no viable skin is left, a split thickness skin graft from the upper thigh will be used. Finally, a healing cap surrounding the healing abutments is placed to ensure strong bone-skin contact around the implant. This healing cap will be fixated by a fixation screw, torqued at 15 Ncm.
- Clinical measurements: The stability of the implants will be measured at the time of abutment placement, 1 or 2 weeks, 1 month, 3 months, 6 months and yearly until the end of the study by resonance frequency analysis (RFA), using the Osstell idx system. At the same time periods the peri-abutment tissue will be evaluated according to the Holgers criteria. Once all implants have reached a stability measurement of 50 ISQ, the patient will be sent to the anaplastologist for prosthesis treatment. In case one or more of the implants fail during the study period, the implant will be removed and replaced by a new implant. The protocol will restart for the newly placed implant.
- Radiological measurements:
The bone level around the implants will be measured at 1 or 2 weeks after implant placement and 1 year after implant placement. Radiological imaging will be performed using a cone beam computed tomography device (planmeca promax 3d max) or CT scan, dependent on primary imaging in order to allow comparison between both images.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study group | Experimental | Device: Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implantsEverybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- All patients with auricular, nasal, orbital defects caused by congenital, traumatic, oncologic or infectious etiologies
- Adults (>18yr)
Key exclusion criteria (3 listed)
- Children
- Implant placement for bone anchored hearing aid (BAHA)
- Implant placement for oral rehabilitation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implantsAlso: EO-1110-34VD04, EO-1110-40VD03, EO-1110-40VD04Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone | Device | Study group |
Primary outcome
Implant survival
Time frame: 1 year
Implant stability measurement with Osstell IDX system
Peri-implant tissue reaction
Time frame: 1 year
Measurement of peri-implant pockets and soft tissue according to Holgers criteria
1 secondary outcome
Bone level
Time frame: 1-2 weeks post-operative, 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2022.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hubert Vermeersch, MD, PhD principal investigator
Em. Professor
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants in people with Maxillofacial Prosthesis Implantation and Extra-oral Implants, run by University Hospital, Ghent at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Implant survival (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2022.